Initiation of sodium-glucose cotransporter 2 inhibitor (SGLT2i) medications reduces risk for hyperkalemia among patients using renin-angiotensin-aldosterone system inhibitors (RAASis) to manage ...

Hyperkalemia, or high potassium levels in the blood, can cause heart arrhythmias and other problems. High potassium treatment depends on how severe it is, whether it came on suddenly, and what’s ...

Results of a recent study found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk for hyperkalemia, greater persistence with renin-angiotensin system ...

In conclusion, In a real-world setting, hypokalemia and hyperkalemia were robustly and consistently reported less frequently with SGLT2 inhibitors than with other diabetes medications. There were ...

Objectives To evaluate the comparative effectiveness of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) ...

There's some evidence that too little potassium-- a nutrient in foods like bananas, squash, and potatoes -- might have a link to diabetes. The reason for the connection: The role of insulin in ...

There are many factors and illnesses that can cause hyperkalemia including kidney disease, heart failure, diabetes mellitus, and certain medications. In adults, a normal potassium blood level is ...

If your level gets above 5.5 mEq/L, you will need treatment right away because elevated levels can become dangerous if they get too high. Hyperkalemia is often caused by kidney disease, but it can be ...

A healthcare professional may use diuretics and potassium binders to flush potassium out of your body if you have hyperkalemia. Intravenous insulin and glucose may help lower potassium levels.

Hyperkalemia is the medical term for high potassium levels. There are often no symptoms of hyperkalemia, but it can be a sign of kidney disease, dehydration, diabetes complications, and many other ...

Hospitalization due to hyperkalemia for the Kerendia group was 0.9% vs 0.2% in the placebo group across both studies. Hyperkalemia led to permanent discontinuation of treatment in 1.7% receiving ...